肿瘤细胞治疗研究
英文原题：Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review.
CAR-T 细胞疗法现已成为几种B细胞恶性肿瘤的标准治疗，更多适应证正在评估中。
CAR-T 细胞疗法现已成为若干B细胞恶性肿瘤的标准治疗方案，更多适应症正在评估中。在这篇综述中，我们调查了CAR-T疗法后结局如何随年龄、种族和民族而变化的数据。我们还回顾了年龄、种族和民族群体在关键CAR-T临床试验中的代表性。我们聚焦于B细胞急性淋巴细胞白血病、B细胞非霍奇金淋巴瘤和多发性骨髓瘤。
Chimeric antigen receptor T cell (CAR-T) therapies are now standard-of-care for several B-cell malignancies, and additional indications are being evaluated. In this review, we survey data on how outcomes after CAR-T therapies vary according to age, race, and ethnicity. We also review the representation of age, racial, and ethnic groups in key CAR-T clinical trials. We focus on B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin's lymphoma, and multiple myeloma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
